Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9682236 | 0.96 | MGAM (0.44) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL4682244 | 0.96 | MGAM (0.44) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL6650078 | 0.96 | MGAM (0.44) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL17481290 | 0.88 | MMP1 (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL12922365 | 0.86 | MGAM (0.54) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL13978415 | 0.84 | MGAM (0.56) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL19864353 | 0.84 | MGAM (0.56) | MGAMGAASIMGAM2MMP1 | |
| Acetoacetic Acid SCHEMBL2189217 | 0.84 | MGAM (0.33) | MGAMGAASIMGAM2MMP1 | |
| SCHEMBL17469488 | 0.80 | MMP1 (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL804588 | 0.80 | MMP1 (0.38) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | BTG INT LTD (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180036274-A1 | USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II | ACCERA, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9175345-B2 | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function | ACCERA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140256808-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8748400-B2 | Use of ketogenic compounds for treatment of age-associated memory impairment | ACCERA, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8445535-B1 | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II | ACCERA, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130079406-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| US-20120122978-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120071548-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-8124589-B2 | Use of ketogenic compounds for treatment of age-associated memory impairment | ACCERA, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8101653-B2 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20110243885-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | ACCERA, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20100261791-A1 | Compositions and Methods for Improving or Preserving Brain Function | ACCERA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100041751-A1 | Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency | ACCERA, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | ACCERA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070179197-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING BRAIN FUNCTION | ACCERA, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070135376-A1 | METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY | ACCERA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071548-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | MGAM 577/4885GAA 315/4885SI 85/4885 |
| US-20110243885-A1 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function | BCKDK, HSD17B12, HSD17B10 | MGAM 471/4885GAA 404/4885SI 2306/4885 |
| US-20100041751-A1 | Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency | GOT2, HADHB, HADHA | MGAM 648/4885GAA 537/4885SI 425/4885 |
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, IAPP, GYS1 | MGAM 542/4885GAA 311/4885SI 91/4885 |
| US-20080287372-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | MGAM 131/4885GAA 416/4885SI 730/4885 |
| US-20070179197-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OR PRESERVING BRAIN FUNCTION | CPT1B, ABHD6, LPL | MGAM 256/4885GAA 529/4885SI 1333/4885 |
| US-20070135376-A1 | METHOD TO REDUCE OXIDATIVE DAMAGE AND IMPROVE MITOCHONDRIAL EFFICIENCY | GOT2, HADHB, HADHA | MGAM 648/4885GAA 537/4885SI 425/4885 |
| US-20140256808-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | MGAM 131/4885GAA 416/4885SI 730/4885 |
| US-20130079406-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, GYS1, IAPP | MGAM 577/4885GAA 315/4885SI 85/4885 |
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, GYS1, IAPP | MGAM 577/4885GAA 315/4885SI 85/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | MGAM 201/4885GAA 348/4885SI 1470/4885 |
| US-20180036274-A1 | USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II | PSEN2, MTTP, APP | MGAM 681/4885GAA 576/4885SI 988/4885 |
| US-20100261791-A1 | Compositions and Methods for Improving or Preserving Brain Function | CPT1B, FABP7, LPL | MGAM 297/4885GAA 452/4885SI 1132/4885 |
| US-20120122978-A1 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment | CPT1B, ACADM, ACAA2 | MGAM 131/4885GAA 416/4885SI 730/4885 |
| US-20090253781-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | MGAM 577/4885GAA 315/4885SI 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.